Physicians' Academy for Cardiovascular Education

EMA positive opinion for use of liraglutide for treatment of obesity

News - Jan. 26, 2015


The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of liraglutide 3 mg for the treatment of obesity.
 

Liraglutide 3 mg, is a once-daily injection of a glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone released in response to food intake and involved in appetite regulation. The CHMP positive opinion recommends that liraglutide will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of > 30 kg/m2 (obese), or > 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
 

Liraglutide is currently approved in the European Union for the treatment of type 2 diabetes at lower doses up to 1.8 mg per day. Liraglutide belongs to a different pharmacological class than other weight management products currently available in the EU. The mechanism by which liraglutide treatment results in weight loss is not entirely understood but it appears to regulate the appetite by increasing feelings of satiety and decreasing hunger.

De CHMP positive opinion is based on data from clinical trials of liraglutide, including the phase 3 SCALE (Satiety and Clinical Adiposity−Liraglutide Evidence in Non-diabetic and Diabetic people). More patients given liraglutide achieved clinically relevant weight loss than those treated with placebo. All patients enrolled in these trials received counselling on diet and physical activity.
clinical development programme, which involved more than 5000 people with obesity or who were overweight with comorbidities.
 

Source

Press release EMA 23 January 2015